Randomized Controlled Trials (RCTs)
January 8, 2020
A randomized controlled trial (RCT) is a widely used method to measure the effectiveness of clinical and pharmaceutical treatments but less commonly used to evaluate health policies. It is the most robust and reliable way to determine if there is a causal link between an intervention, such as a drug or policy, and a desired effect, such as weight loss.
In the inaugural edition of our series, The Sidebar, co-hosts Dan Gorensten and Sayeh Nikpay dive a bit deeper into the RCT as a policy evaluation tool. How do these trials work and what are some of their tradeoffs?
Listen to the conversation below or scroll down for more information.
How Does It Work?
At its most basic level, an RCT is trying to answer a question: Does an intervention (a drug, a treatment, a policy, etc.) make a significant difference in achieving a particular outcome?
To do that, researchers randomly assign a group of people to two different groups: one that receives the intervention and one that doesn’t. The one that doesn’t receive the intervention is known as the “control” group, and it provides a baseline to which the effect of the intervention can be compared.
Health Policy RCTs You Should Know...
What: Compared how different levels of cost sharing impacted health care spending, quality of care and health outcomes.
Why it matters: It demonstrated people use less care when they pay out of pocket and is often cited as evidence that high-deductible health plans and high conisurance may hurt patients.
What: Studied impact of Medicaid expansion by comparing those selected via lottery to receive expansion and those not selected.
Why it matters: One of, if not the largest health care policy studies in U.S. history. Demonstrated numerous positive effects of Medicaid.
Understanding and Misunderstanding Randomized Controlled Trials (Angus Deaton and Nancy Cartwright, National Bureau of Economic Research, 2017)
Evidence for Health Decision Making — Beyond Randomized, Controlled Trials (Thomas Frieden, New England Journal of Medicine, 2017)
In Defense of the Randomized Controlled Trial for Health Promotion Research (Laura Rosen, Orly Manor, Dan Engelhard and David Zucker; American Journal of Public Health, 2006)
Using Randomized Evaluations to Improve the Efficiency of US Healthcare Delivery (Amy Finkelstein and Sarah Taubman, J-PAL North America, 2015)
Mostly Harmless Econometrics, Chapter 2 (Joshua Angrist and Jorn-Steffen Pischke, 2008)